Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jianmin Li has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, representing a very specific and narrow prosecution focus for the current portfolio. The focus on 1 distinct art unit indicates that the current patenting activity is concentrated in a single specialized area of biotechnology rather than across multiple scientific fields.
MOREAU, NASHARA LOUISE is the busiest examiner with 1 pending office action. This examiner manages the only active matter for the portfolio, meaning the immediate success of the prosecution strategy depends on the interaction with this single examiner. With 1 pending office action in the entire portfolio, the applicant must carefully address the specific concerns of this examiner, as there are no other pending matters to provide alternative avenues for securing patent protection. The resolution of the 1 pending office action is the primary hurdle for the portfolio's advancement.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 80.0% | -100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012533 | MYCELIAL CULTURE OF Irpex lacteus AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF DIABETES MEILLITUS | MOREAU, NASHARA LOUISE | 8d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012533 | MYCELIAL CULTURE OF Irpex lacteus AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF DIABETES MEILLITUS | MOREAU, NASHARA LOUISE | 1655 | §101§103§112 | Final Rejection | 8d | Pending | Mar 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial